Clinical Trial Update: Clinical Study on the Safety and Tolerability of Macitentan in Combination With Dose-dense Temozolomide in Patients With Recurrent Glioblastoma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and tolerability of macitentan in combination with dose-dense temozolomide in recurrent glioblastoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Macitentan (macitentan)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Actelion | Conditions: Glioblastoma | Phase 1 | Status: TERMINATED